Oncology Drug Cost Sharing Would Decline 42% Under Medicare Part D Redesign
Executive Summary
Cost sharing reductions resulting from US Senate drug pricing legislation would vary across categories but the biggest decreases are likely for oncology drugs, antidiabetics and psychotherapeutics, a recent analysis by Manatt Health finds.
You may also be interested in...
Amylyx ALS Drug May Drive Medicare Part D Redesign Efforts Based On Cost Sharing Concerns
Medicare could be an important payer for the eagerly awaited drug because the program covers ALS treatments for patients under 65 as well as older ones. Meanwhile, a draft Institute for Clinical and Economic Review raises questions about the drug's cost effectiveness.
Part D Redesign: MedPAC Finalizes Recommendations To Congress But COVID-19 Will Get In The Way
Plan includes new 30% manufacturer discount in the US Medicare Part D catastrophic phase, which manufacturers will oppose as too high. But it also caps beneficiary cost sharing, a long-sought industry goal.
Medicare Could Save More than $80bn With Price Inflation Rebates – CBO Score of Senate Bill
Nearly $70bn in savings over 10 years is expected to result from mandatory price inflation rebates for drugs covered by Medicare Part D.